argenx
Clinical trials sponsored by argenx, explained in plain language.
Biopharmaceutical company developing antibody therapies for autoimmune diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug aims to replace IVIg for nerve disease Results expected Sep 2026 (estimated) May already have reported ↗
- Can a Pen-Style injector match a syringe for delivering efgartigimod? Results expected Sep 2026 (estimated)
- New shot shows promise for long-term platelet control in rare bleeding disorder Results expected Oct 2026 (estimated) May already have reported ↗
- New drug hopes to tame rare muscle and skin disease Results expected Nov 2026 (estimated)
- Scientists test how body weight influences a new drug's absorption Results expected Dec 2026 (estimated)
-
ALS drug trial halted: ARGX-119 fails to show promise
Disease control Stopped earlyThis study tested an experimental drug called ARGX-119 in 60 adults with ALS. The goal was to see if it was safe and could help with muscle function. The trial was stopped early because early results showed it was unlikely to make a meaningful difference. No safety concerns trigg…
Phase 2 • Sponsor: argenx • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Thyroid eye disease drug trial halted early – no safety concerns
Disease control Stopped earlyThis study tested a drug called efgartigimod for people with active, moderate-to-severe thyroid eye disease, a condition that causes bulging eyes and vision problems. About 102 adults took part, receiving either the drug or a placebo. The trial was stopped early because early res…
Phase 3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Thyroid eye disease drug trial halted after early results disappoint
Disease control Stopped earlyThis study tested a drug called efgartigimod for people with active, moderate-to-severe thyroid eye disease, a condition that causes bulging eyes and vision problems. About 105 adults were randomly assigned to receive either the drug or a placebo as a shot under the skin. The tri…
Phase 3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug shows promise for blistering skin disease in extended trial
Disease control Stopped earlyThis study looks at the long-term safety of a drug called efgartigimod for adults with moderate-to-severe bullous pemphigoid, a condition that causes painful blisters. Participants who finished the main study can continue treatment for up to 48 weeks, with the option to pause and…
Phase 3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Experimental drug for Post-COVID POTS study halted early
Disease control Stopped earlyThis study looked at the long-term safety of efgartigimod in adults with post-COVID postural orthostatic tachycardia syndrome (POTS), a condition causing rapid heart rate and dizziness upon standing. The trial was an open-label extension for people who completed a previous study.…
Phase 2 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC